NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
Read this Release on Our Investor Relations Website | PDF Version -- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4…
Read More
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway
First patient receives brain-responsive neuromodulation for LGS, a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif., November 30, 2022--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage…
Read More
NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)
Groundbreaking NAUTILUS study will evaluate the safety and effectiveness of the RNS System to treat generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…
Read More
NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents
RESPONSE Study first to evaluate the effectiveness of brain-responsive neuromodulation to treat focal epilepsy in patients 12 through 17 MOUNTAIN VIEW, Calif. — May 4,…
Read More
NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy
IDE study will be first to evaluate the effectiveness of brain-responsive neuromodulation to treat primary generalized epilepsy in patients aged 12 and older MOUNTAIN VIEW,…
Read More
NeuroPace Launches nSight Platform and Partnership with Seizure Tracker™ to Provide Doctors With Personalized Information About Their Patients’ Seizure Burden
New Online Physician Portal Integrates RNS System’s EEG Data with Patient Seizure Diary App to Help Doctors Provide More Comprehensive, Data-Driven Care for Epilepsy Patients…
Read More
NeuroPace Awarded Five-Year NIH Grant Funding of More than $9M to Study RNS System in Patients with Lennox-Gastaut Syndrome
Feasibility IDE study will be the first to evaluate responsive neuromodulation for a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif. — June 30, 2021…
Read More
NeuroPace Receives FDA Breakthrough Device Designation for RNS System for Idiopathic Generalized Epilepsy
Company plans to pursue indication expansion to broaden access to include patients with second most common type of epilepsy. MOUNTAIN VIEW, Calif. – March 31,…
Read More
NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy
Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif. – August 31, 2020 – NeuroPace,…
Read More
New Published Data Show NeuroPace’s RNS® System Provides Patients with Unprecedented Seizure Reduction and Improved Quality of Life
Personalized, data-driven treatment for refractory focal epilepsy demonstrates unprecedented real-world results and exceptional long-term clinical data MOUNTAIN VIEW, Calif. – July 27, 2020 – NeuroPace,…
Read More
NeuroPace RNS System Receives FDA Approval for MRI Labeling, Allowing Thousands More Patients to Benefit from Personalized, Data-Driven Epilepsy Treatment
Full-body MRI opens up valuable medical imaging possibilities for RNS System patients MOUNTAIN VIEW, Calif. – March. 9, 2020 – NeuroPace, Inc., a Silicon Valley-based…
Read More
New Data Presented at the American Epilepsy Society Annual Meeting Demonstrate Unprecedented Efficacy Outcomes with the NeuroPace RNS System
Real-world experience with the RNS System reveals best outcomes to date of any neuromodulation device for focal seizures MOUNTAIN VIEW, Calif. — December 9, 2019…
Read More
